Thanks for the article. I just had a quick read. Interesting in respect to what PIQ’s new Patent in drug development in Kidney disease granted in the USA, ANN’d some time ago, also PromarkerD.
Interestingly enough, this company Goldfinch are targeting FSGS & NASH in their own pipeline as well as this deal on genomic mapping & a genomic mapping in DKD. I am also invested in DXB whom PIQ have partnered with in Ph2b trials & interestingly enough, we are in trials now for DKD & FSGS. Some time ago, we had a NASH targeting drug also in pipeline development, but in the pipeline is now ‘undisclosed’, & all drugs identified by HIT Receptor technology & IP on both. Previously they were licensing out HIT Receptor & now not. A very long cross over dual trials & so you can understand SP.
2 little Aussie Biotechs who are in later stages of development with good IP, whom both have been rather quiet lately. 2b for DXB & I’m sure they will want to know this information too.
I see you haven’t bought here yet, but I & others appreciate your thoughts & respect your posts, some other boards I have read, BIT maybe not, but this is a completely different clinical area. Well when you get the time, @Davisite. Thanks again as relevant & will generate some interesting discussion at the least . I better go pop over to DXB & share the articles. Best wishes all.
PIQ Price at posting:
30.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
. I better go pop over to DXB & share the articles. Best wishes all.
(20min delay)